Sirrs S - Search Results

1

Echocardiographic Assessment of Patients with Fabry Disease.

Yeung DF, Sirrs S, Tsang MYC, Gin K, Luong C, Jue J, Nair P, Lee PK, Tsang TSM. Yeung DF, et al. Among authors: sirrs s. J Am Soc Echocardiogr. 2018 Jun;31(6):639-649.e2. doi: 10.1016/j.echo.2018.01.016. Epub 2018 Mar 29. J Am Soc Echocardiogr. 2018. PMID: 29606333 Review.

2

High rate of hypertension in patients with m.3243A>G MELAS mutations and POLG variants.

Pauls AD, Sandhu V, Young D, Nevay DL, Yeung DF, Sirrs S, Tsang MY, Tsang TSM, Lehman A, Mezei MM, Poburko D. Pauls AD, et al. Among authors: sirrs s. Mitochondrion. 2020 Jul;53:194-202. doi: 10.1016/j.mito.2020.05.011. Epub 2020 Jun 2. Mitochondrion. 2020. PMID: 32502631

3

Failure of resting echocardiography and cardiac catheterization to identify pulmonary hypertension in two patients with type I Gaucher disease.

Sirrs S, Irving J, McCauley G, Gin K, Munt B, Pastores G, Mistry P. Sirrs S, et al. J Inherit Metab Dis. 2002 May;25(2):131-2. doi: 10.1023/a:1015680827730. J Inherit Metab Dis. 2002. PMID: 12118528

4

Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test.

Andrade J, Waters PJ, Singh RS, Levin A, Toh BC, Vallance HD, Sirrs S. Andrade J, et al. Among authors: sirrs s. Clin J Am Soc Nephrol. 2008 Jan;3(1):139-45. doi: 10.2215/CJN.02490607. Epub 2007 Nov 14. Clin J Am Soc Nephrol. 2008. PMID: 18003767 Free PMC article. Clinical Trial.

5

Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative.

Sirrs S, Clarke JT, Bichet DG, Casey R, Lemoine K, Flowerdew G, Sinasac DS, West ML. Sirrs S, et al. Mol Genet Metab. 2010 Apr;99(4):367-73. doi: 10.1016/j.ymgme.2009.11.001. Epub 2009 Nov 16. Mol Genet Metab. 2010. PMID: 20022777 Clinical Trial.

6

The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process.

Khan A, Sirrs SM, Bichet DG, Morel CF, Tocoian A, Lan L, West ML; Canadian Fabry Disease Initiative. Khan A, et al. Among authors: sirrs sm. Drugs R D. 2021 Dec;21(4):385-397. doi: 10.1007/s40268-021-00361-4. Epub 2021 Sep 20. Drugs R D. 2021. PMID: 34542871 Free PMC article.

7

Outcomes of patients treated through the Canadian Fabry disease initiative.

Sirrs SM, Bichet DG, Casey R, Clarke JT, Lemoine K, Doucette S, West ML; CFDI investigators. Sirrs SM, et al. Mol Genet Metab. 2014 Apr;111(4):499-506. doi: 10.1016/j.ymgme.2014.01.014. Epub 2014 Feb 2. Mol Genet Metab. 2014. PMID: 24534763 Clinical Trial.

8

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.

Arends M, Biegstraaten M, Wanner C, Sirrs S, Mehta A, Elliott PM, Oder D, Watkinson OT, Bichet DG, Khan A, Iwanochko M, Vaz FM, van Kuilenburg ABP, West ML, Hughes DA, Hollak CEM. Arends M, et al. Among authors: sirrs s. J Med Genet. 2018 May;55(5):351-358. doi: 10.1136/jmedgenet-2017-104863. Epub 2018 Feb 7. J Med Genet. 2018. PMID: 29437868 Free PMC article.

9

Enzyme replacement therapy for Fabry disease: some answers but more questions.

Alfadhel M, Sirrs S. Alfadhel M, et al. Among authors: sirrs s. Ther Clin Risk Manag. 2011;7:69-82. doi: 10.2147/TCRM.S11987. Epub 2011 Feb 25. Ther Clin Risk Manag. 2011. PMID: 21445281 Free PMC article.

10

Hematopoietic Stem Cell Transplantation in Late-Onset Krabbe Disease: No Evidence of Worsening Demyelination and Axonal Loss 4 Years Post-allograft.

Laule C, Vavasour IM, Shahinfard E, Mädler B, Zhang J, Li DKB, MacKay AL, Sirrs SM. Laule C, et al. J Neuroimaging. 2018 May;28(3):252-255. doi: 10.1111/jon.12502. Epub 2018 Feb 26. J Neuroimaging. 2018. PMID: 29479774

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

86 results

Search Page